Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)

Maria Giuseppa Vitale, Sergio Bracarda, Laura Cosmai, Emanuele Crocetti, Giuseppe Di Lorenzo, Alberto Lapini, Alberto Mandressi, Giuseppe Martorana, Cristina Masini, Rodolfo Montironi, Cinzia Ortega, Rodolfo Passalacqua, Camillo Porta, Giuseppe Procopio, Pierangela Sepe, Luigia Romano, Giovanni Luigi Pappagallo, Giario Conti, Michele Guida, Guido MartignoniFranco Nolè, Sandro Pignata, Stefania Gori, Giacomo Cartenì

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.

Original languageEnglish
Pages (from-to)3-12
Number of pages10
JournalTumori
Volume105
Issue number4_suppl
DOIs
Publication statusPublished - Jul 1 2019

Fingerprint

Medical Oncology
Kidney Neoplasms
Renal Cell Carcinoma
Guidelines
Molecular Targeted Therapy
Vascular Endothelial Growth Factor A
Therapeutics

Keywords

  • AIOM
  • guidelines
  • Italian
  • recommendation
  • renal cell cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Management of kidney cancer patients : 2018 guidelines of the Italian Medical Oncology Association (AIOM). / Giuseppa Vitale, Maria; Bracarda, Sergio; Cosmai, Laura; Crocetti, Emanuele; Di Lorenzo, Giuseppe; Lapini, Alberto; Mandressi, Alberto; Martorana, Giuseppe; Masini, Cristina; Montironi, Rodolfo; Ortega, Cinzia; Passalacqua, Rodolfo; Porta, Camillo; Procopio, Giuseppe; Sepe, Pierangela; Romano, Luigia; Luigi Pappagallo, Giovanni; Conti, Giario; Guida, Michele; Martignoni, Guido; Nolè, Franco; Pignata, Sandro; Gori, Stefania; Cartenì, Giacomo.

In: Tumori, Vol. 105, No. 4_suppl, 01.07.2019, p. 3-12.

Research output: Contribution to journalArticle

Giuseppa Vitale, M, Bracarda, S, Cosmai, L, Crocetti, E, Di Lorenzo, G, Lapini, A, Mandressi, A, Martorana, G, Masini, C, Montironi, R, Ortega, C, Passalacqua, R, Porta, C, Procopio, G, Sepe, P, Romano, L, Luigi Pappagallo, G, Conti, G, Guida, M, Martignoni, G, Nolè, F, Pignata, S, Gori, S & Cartenì, G 2019, 'Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)', Tumori, vol. 105, no. 4_suppl, pp. 3-12. https://doi.org/10.1177/0300891619853392
Giuseppa Vitale, Maria ; Bracarda, Sergio ; Cosmai, Laura ; Crocetti, Emanuele ; Di Lorenzo, Giuseppe ; Lapini, Alberto ; Mandressi, Alberto ; Martorana, Giuseppe ; Masini, Cristina ; Montironi, Rodolfo ; Ortega, Cinzia ; Passalacqua, Rodolfo ; Porta, Camillo ; Procopio, Giuseppe ; Sepe, Pierangela ; Romano, Luigia ; Luigi Pappagallo, Giovanni ; Conti, Giario ; Guida, Michele ; Martignoni, Guido ; Nolè, Franco ; Pignata, Sandro ; Gori, Stefania ; Cartenì, Giacomo. / Management of kidney cancer patients : 2018 guidelines of the Italian Medical Oncology Association (AIOM). In: Tumori. 2019 ; Vol. 105, No. 4_suppl. pp. 3-12.
@article{c9a52524d932435ab372824211051d11,
title = "Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM)",
abstract = "In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.",
keywords = "AIOM, guidelines, Italian, recommendation, renal cell cancer",
author = "{Giuseppa Vitale}, Maria and Sergio Bracarda and Laura Cosmai and Emanuele Crocetti and {Di Lorenzo}, Giuseppe and Alberto Lapini and Alberto Mandressi and Giuseppe Martorana and Cristina Masini and Rodolfo Montironi and Cinzia Ortega and Rodolfo Passalacqua and Camillo Porta and Giuseppe Procopio and Pierangela Sepe and Luigia Romano and {Luigi Pappagallo}, Giovanni and Giario Conti and Michele Guida and Guido Martignoni and Franco Nol{\`e} and Sandro Pignata and Stefania Gori and Giacomo Carten{\`i}",
year = "2019",
month = "7",
day = "1",
doi = "10.1177/0300891619853392",
language = "English",
volume = "105",
pages = "3--12",
journal = "Tumori",
issn = "0300-8916",
publisher = "SAGE Publications Ltd",
number = "4_suppl",

}

TY - JOUR

T1 - Management of kidney cancer patients

T2 - 2018 guidelines of the Italian Medical Oncology Association (AIOM)

AU - Giuseppa Vitale, Maria

AU - Bracarda, Sergio

AU - Cosmai, Laura

AU - Crocetti, Emanuele

AU - Di Lorenzo, Giuseppe

AU - Lapini, Alberto

AU - Mandressi, Alberto

AU - Martorana, Giuseppe

AU - Masini, Cristina

AU - Montironi, Rodolfo

AU - Ortega, Cinzia

AU - Passalacqua, Rodolfo

AU - Porta, Camillo

AU - Procopio, Giuseppe

AU - Sepe, Pierangela

AU - Romano, Luigia

AU - Luigi Pappagallo, Giovanni

AU - Conti, Giario

AU - Guida, Michele

AU - Martignoni, Guido

AU - Nolè, Franco

AU - Pignata, Sandro

AU - Gori, Stefania

AU - Cartenì, Giacomo

PY - 2019/7/1

Y1 - 2019/7/1

N2 - In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.

AB - In the past two decades, the treatment landscape for patients with metastatic renal cell carcinoma has significantly changed thanks to the approval of several targeted molecular therapies (VEGF and mTOR inhibitors) and recently immune-checkpoint inhibitors. The Italian Association of Medical Oncology (AIOM) Renal Cell Cancer (RCC) Guidelines Panel has developed clinical guidelines to provide evidence-based information and recommendations to oncologists, urologists and all professionals involved in the management of patients with renal cell cancer.

KW - AIOM

KW - guidelines

KW - Italian

KW - recommendation

KW - renal cell cancer

UR - http://www.scopus.com/inward/record.url?scp=85069269872&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069269872&partnerID=8YFLogxK

U2 - 10.1177/0300891619853392

DO - 10.1177/0300891619853392

M3 - Article

C2 - 31264522

AN - SCOPUS:85069269872

VL - 105

SP - 3

EP - 12

JO - Tumori

JF - Tumori

SN - 0300-8916

IS - 4_suppl

ER -